Long-Term Continuous Corticosterone Treatment Decreases VEGF Receptor-2 Expression in Frontal Cortex by Howell, Kristy R. et al.
Long-Term Continuous Corticosterone Treatment





1Department of Psychiatry and Health Behavior, Georgia Health Sciences University, Augusta, Georgia, United States of America, 2Medical Research Service, Charlie
Norwood Veterans Affairs Medical Center, Augusta, Georgia, United States of America
Abstract
Objective: Stress and increased glucocorticoid levels are associated with many neuropsychiatric disorders including
schizophrenia and depression. Recently, the role of vascular endothelial factor receptor-2 (VEGFR2/Flk1) signaling has been
implicated in stress-mediated neuroplasticity. However, the mechanism of regulation of VEGF/Flk1 signaling under long-
term continuous glucocorticoid exposure has not been elucidated.
Material and Methods: We examined the possible effects of long-term continuous glucocorticoid exposure on VEGF/Flk1
signaling in cultured cortical neurons in vitro, mouse frontal cortex in vivo, and in post mortem human prefrontal cortex of
both control and schizophrenia subjects.
Results:Wefoundthatlong-termcontinuousexposuretocorticosterone (CORT,anaturalglucocorticoid)reducedFlk1protein
levels both in vitro andin vivo. CORT treatment resultedinalterationsinsignaling moleculesdownstream to Flk1 such as PTEN,
AktandmTOR.WedemonstratedthatCORT-inducedchangesinFlk1levelsaremediatedthrough glucocorticoidreceptor(GR)
and calcium. A significant reduction in Flk1-GR interaction was observed following CORT exposure. Interestingly, VEGF levels
were increased in cortex, but decreased in serum following CORT treatment. Moreover, significant reductions in Flk1 and GR
protein levels were found in postmortem prefrontal cortex samples from schizophrenia subjects.
Conclusions: The alterations in VEGF/Flk1 signaling following long-term continuous CORT exposure represents a molecular
mechanism of the neurobiological effects of chronic stress.
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Introduction
Stress and elevated glucocorticoid levels are known to be
associated with a number of neuropsychiatric disorders including
depression and schizophrenia. Although acute treatment with
corticosteroid is shown to be neuroprotective [1] their chronic
effects are deleterious to the structural and functional plasticity of
adult brain [2]. Moreover, many of the effects of chronic stress are
thought to be mediated by stress-induced increases in circulating
levels of glucocorticoids [3,4]. Animal studies have shown a number
of behavioral abnormalities similar to depression and anxiety
followingchronicadministration ofglucocorticoids [5–7].However,
the mechanism underlying long-term continuous glucocorticoid-
induced alterations in neuroplasticity is still not clear.
Vascular endothelial growth factor (VEGF) is a neuroprotective,
angiogenic and neurotrophic molecule [8]. VEGF is known to
mediate its biological functions via activation of the protein
tyrosine kinase receptors, VEGF receptor 1 (VEGFR-1/Flt1) and
VEGFR-2 (KDR/Flk1) [9]. VEGF and its receptors are expressed
on neurons and astrocytes, and VEGF induces neuronal
outgrowth. Flk1 has been shown to mediate VEGF action in
neuronal functions [10,11] and activation of Flk1 allows the
receptors to associate with various downstream effector molecules
including phosphatidylinositol 3-kinase (PI3K) [12,13]. PI3K/Akt
signal transduction pathway has been identified as an important
mediator VEGF signaling downstream of Flk1 [14].
The prefrontal cortex (PFC) is a brain region involved in higher-
order cognitive and affective processing, as well as executive
function [15,16]. The PFC is also a target region for glucocorticoid
effects, as it has a rich population of glucocorticoid receptors
[17,18]. High doses of glucocorticoids are known to impair PFC-
dependent working memory in rodents [19,20] and humans
[21].Chronic corticosterone (CORT) treatment has also been
shown to produce neuronal impairment in the PFC including the
remodeling of pyramidal neurons, significantly reduced distal
dendritic spines of neurons and neuronal loss [22–24]. VEGF
signaling is known to play an important role in cognitive functions
and neuroprotection [10,11]. A recent study has shown that
pharmacological inhibition of Flk1 signaling can block the
behavioral actions of fluoxetine in rats subjected to chronic stress
[25] indicating a possible role of Flk1 signaling in stress-mediated
behavioral changes. However, the effects of chronic glucocorticoid
on VEGF signaling remain unknown. Specifically it is not known
whether long-term continuous glucocorticoid exposure can cause
alterations in VEGF signaling pathway in PFC. Studies on the
effect of glucocorticoids on VEGF signaling might provide
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20198valuable information on the molecular mechanism of the
neurobiological effects of chronic glucocorticoid exposure.
In the present article, we investigated the effects of long-term
continuous CORT exposure on VEGF/Flk1 signaling in cultured
cortical neurons in vitro, mouse frontal cortex in vivo, and in post
mortem human prefrontal cortex of both control and schizophre-
nia subjects.
Results
Long-term Continuous CORT Treatment Does Not
Change Neuronal Cell Viability
Neuronal cell viability was measured at 48, 72 and 96 h
exposure of cortical neurons by MTT assay. We did not find any
significant change in neuronal cell viability at any of the treatment
point in CORT (I mM) treated cells as compared to vehicle treated
cells (data not shown).
Long-term Continuous CORT Treatment Decreases Flk1
Protein Levels in vitro and in vivo
Expression of Flk1 was examined at 12, 24, 48 and 72 h exposure
of primary cortical neurons to CORT or vehicle by western blot
analysisusing Flk1 antibody. The densitometric valuesforFlk1were
corrected for b-actin. No change in Flk1 protein levels was found at
12 and 24 h following CORT treatment (data not shown). In 24
and 48 h treatment groups, data from two-way ANOVA revealed a
significant time x treatment interaction [F(1, 20)=19.27, p,0.01],
but no significant main effect of time [F(1,20)=0.382, N.S.] or
treatment [F(1, 20)=0.555, N.S.]. Post hoc analysis by Bonferroni’s
Multiple Comparison test showed a significant decrease in Flk1
protein levels at 48 h (t=4.112, p,0.05), which lasted up to at least
72 h (t=3.977, p,0.05) (Fig. 1A). Next, we examined Flk1 protein
levels in mice treated with CORT for 7 weeks.Western blot analysis
showed a significant decrease in Flk1 protein levels in frontal cortex
of mice treated with CORT for 7 weeks as compared to vehicle-
treated mice (Fig. 1B; t=3.323, df=10, p=0.0039). In addition, we
found a significant decrease in serum Flk1 protein levels in mice
treated with CORT for 7 weeks (113.1869.55 ng/mL vs 78.636
5.77 ng/mL (mean6SE); t=2.702, df=8, p=0.035).
Long-term Continuous CORT Treatment Alters p-PTEN,
p-Akt and p-mTOR Levels in Cortical Neurons
Several studies have reported PTEN/Akt/mTOR pathway as a
key downstream signaling to Flk1 [14]. To determine whether the
changes in Flk1 protein levels result in alterations in its downstream
signaling pathway, the PTEN/Akt/mTOR pathway was investigat-
ed. Cortical neurons were exposed to CORT for 48 or 72 h, and
equal amounts of lysates were separated by PAGE and immuno-
blotted using phosphospecific PTEN antibody. The two-way
ANOVA revealed significant effects of treatment [F(1, 20) =5.7,
p,0.05], time [F(1, 20)=5.77, p,0.01] and time x treatment
interaction [F(1,20)=9.246, p,0.05]. Subsequent comparisons by
Bonferroni’s Multiple Comparison test indicated that CORT
significantly stimulated the phosphorylation of PTEN at 48 h of
exposure compared with the control group (Fig. 2A; t=3.838,
p,0.05). However, a significant reduction in phospho-PTEN levels
were found at 72 h as compared to levels at 48 h (t=4.833, p,0.01),
but no change as compared to vehicle-treated cells. Next, we
examined the effect of CORT treatment on phospho-Akt levels in
neurons. Data from two-way ANOVA showed a significant effect of
treatment [F(1, 20)=30.43, p,0.001], but no time x treatment
interaction [F(1, 20)=0.353, N.S.] or main effect of time
[F(1,20)=0.002, N.S.]. Post hoc analysis showed a significant
reduction in phospho-Akt levels at 48 h following CORT treatment
as measured by phosphorylation of serine 473 (Fig. 2B;t = 4 . 4 7 2 ,
p,0.01). Also, a significant reduction in phospho Akt levels was
observed when examined at 72 h following CORT treatment
(t=3.37,p,0.05).SincemTORhasacriticalfunctionintransducing
signals from PI3K/Akt cascade, we next investigated the activation
status of mTOR in neurons following CORT treatment. We found
significant effects of treatment [F(1, 20)=35.84, p,0.001], time
[F(1,20)=5.774, p,0.05] and time x treatment interaction [F(1,
20)=6.786, p,0.05]. Post hoc analysis showed a significant
reduction in phospho-mTOR levels at 48 h (t=7.238, p,0.001)
and 72 h (t=3.581, p,0.05) following CORT exposure (Fig. 2C).
Effects of Long-term Continuous CORT Treatment on
VEGF Protein Levels in vitro and in vivo
To examine whether CORT treatment alters VEGF expression
in cortex, we analysed VEGF protein levels in primary cortical
Figure 1. Long-term Continuous CORT treatment decreases
Flk1 protein levels in vitro and in vivo. (A) CORT (CORT; I mM) was
applied to mouse primary cortical neurons at DIV 5. Flk1 protein levels
were determined by western blotting analysis at 48 hand 72 h
following CORT treatment. CON means DMSO treatment. Data
represent mean6SE. (n=6) expressed as fold change in Flk1 protein
levels as compared to CON. b-actin is the loading control. *P,0.05
(Bonferroni’s test). (B) Flk1 protein levels in frontal cortex of mice
treated with CORT or vehicle control (CON; 0.45% hydroxypropyl-b-
cyclodextrin) for 7 weeks. Data represent mean6SE (n=6–8) expressed
as fold change in Flk1 protein levels as compared to CON. *P,0.01
(t test).
doi:10.1371/journal.pone.0020198.g001
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CORT for 7 weeks. In 24 and 48 h treatment groups, data from
two-way ANOVA revealed a significant time x treatment
interaction [F(1, 20)=28.37, p,0.001], main effect of time
[F(1,20)=52.42, p,0.001] and treatment [F(1, 20)=21.656,
p,0.01]. Post hoc analysis showed that VEGF level was
dramatically increased by nearly 56% when examined at 48 h of
CORT exposure (Fig. 3A; t=4.676, p,0.05), which lasted up to
at 72 h (t=3.856, p,0.05). We found a significant increase in
VEGF protein levels in frontal cortex of mice treated with CORT
for 7 weeks as compared to vehicle-treated mice (Fig. 3B; t=10.04,
df=8, p,0.0001). In addition, we have examined VEGF levels in
serum samples collected from mice treated with vehicle or CORT
for 7 weeks. We found a significant decrease in serum VEGF levels
following CORT treatment (Fig. 3C; t=2.39, df=9, p=0.04).
PI3K Signaling Is Not Involved in Long-term Continuous
CORT-induced Increases in VEGF Protein Levels
Since PI3K signaling is also involved in the regulation of VEGF
expression, we examined whether the changes in the above signaling
molecules observed following CORT exposure are upstream to
VEGF.Inthefirstsetofexperiments,wedeterminedtheroleofPI3K
signaling in the regulation of VEGF expression. Cortical neurons
were treated with PI3K inhibitor, LY294002 (LY) and VEGF protein
levels were determined by immunoblotting analysis. We found a
significant reduction in VEGF protein levels in neurons treated with
LY for 48 h indicating a possible role of PI3K in VEGF regulation
(Fig. 4A; t=6.975; df=10, p=0.002). Next, we examined whether
LY294002 can attenuate CORT-induced increases in VEGF protein
levels.LYfailed toinhibit CORT-induced increasein VEGF levelsin
neurons (Fig. 4B) indicating pathways other than PI3K might be
involved in CORT-induced VEGF regulation.
Long-term Continuous CORT-induced Flk1 Regulation Is
Mediated Through Calcium
CORT treatment can regulate concentration of intracellular
calcium ions (Ca
2+) by modulating extracellular Ca
2+ influx and
intracellular Ca
2+ pools [31–33]. To assess whether Ca
2+
contributed to Flk1 regulation by chronic CORT exposure, we
treated neurons with the membrane-permeable chelator BAPTA-
AM. Application of BAPTA-AM abolished the decrease in Flk1
protein levelsobserved inthe presenceofCORT alone(Fig.5A;F(3,
16)=19.02; p,0.01). In addition, a significant increase in Flk1
expression was found in cells treated with BAPTA-AM alone as
Figure 2. Long-term Continuous CORT treatment alters phospho PTEN, phospho Akt and phospho mTOR protein levels in cortical
neurons. CORT (CORT; I mM) was applied to mouse primary cortical neurons at DIV 5. Cell lysates collected at 48 h or 72 h following CORT treatment
were used for western blot analysis. CON means DMSO treatment. Data represent mean6SE (n=6) expressed as fold change in (A) phospho PTEN to
total PTEN ratio, (B) phospho Akt to total Akt ratio and (C) phospho mTOR to total mTOR ratio as compared to CON. *P,0.01 versus CON; #P,0.01
versus values at 48 h (Bonferroni’s test).
doi:10.1371/journal.pone.0020198.g002
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mediating CORT effects on Flk1 protein levels was further studied
by examining the protein levels of neuronal calcium sensor-1 (NCS-
1) in primary cortical neurons as well as in mouse frontal cortex
following CORT exposure. NCS-1 is the mammalian ortholog of
frequenin, a calcium-binding protein implicated in mediating
several aspects of neurotransmission, including ion channel
regulation [34,35] and neurotransmitter release [36–38]. We found
a significant increase in NCS-1 protein levels in cortical neurons
treated with CORT for 48 h (Fig. 5B; t=3.369; df=8, p=0.0281).
A significant increase in NCS-1 protein levels was also found in the
frontal cortex of mice treated with CORT for 7 weeks (Fig. 5C;
t=6.145, df=10, p=0.0036). Our data suggest that the intracel-
lular concentrations of Ca
2+ are regulated by CORT, and increased
Ca
2+ may be involved in the downregulation of Flk1 by CORT.
Long-term Continuous CORT Treatment Decreases
Serum CORT Levels
CORT levels were analysed in the serum samples collected
from mice treated with vehicle or CORT for 7 weeks. We found a
significant reduction in serum CORT levels in CORT-treated
mice [113.2614.43 ng/mL vs 45.2569.78 ng/mL (mean6SE);
t=3.659, df=8, p=0.008].
GR Downregulation Is Involved in Long-term Continuous
CORT-induced Downregulation of Flk1
We examined the possible role of GR in chronic CORT-
induced Flk1 downregulation. We found a significant reduction in
GR protein levels at 48 h following CORT treatment in cortical
neurons (Fig. 6A; t=2.981, df=8, p=0.04). A significant
Figure 3. Long-term Continuous CORT treatment increases VEGF protein levels in vitro and in vivo. (A) CORT (CORT; 1 mM) was applied to
mouse primary cortical neurons at DIV 5. VEGF protein levels were determined by western blotting analysis at 48 hand 72 h following CORT
treatment. CON means DMSO treatment. Data represent mean6SE (n=6) expressed as fold change in VEGF protein levels as compared to CON.
*P,0.05 (Bonferroni’s test). (B) VEGF protein levels in frontal cortex of mice treated with CORT (5 mg/kg) or vehicle control (CON; 0.45%
hydroxypropyl-b-cyclodextrin) for 7 weeks were determined by western blot analysis. Data represent mean6SE (n=5) expressed as fold change in
VEGF protein levels as compared to CON. *P,0.01 (t test). (C) VEGF protein levels in serum samples collected from mice treated with CORT (CORT;
5 mg/kg) or vehicle control (CON; 0.45% hydroxypropyl-b-cyclodextrin) for 7 weeks were analysed by ELISA. Data represent mean6SE (n=5–6)
expressed as fold change in VEGF protein levels as compared to CON. *P,0.01 (t test).
doi:10.1371/journal.pone.0020198.g003
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treated with CORT for 7 weeks (Fig. 6B; t=4.05, df=8,
p=0.015). Pretreatment with RU486 (a GR antagonist) prevented
GR downregulation by CORT in neurons (Fig. 6C; F(3, 16) =
12.70, p,0.01). In addition, CORT-induced reduction in Flk1
was not observed when neurons were treated with CORT and
RU486 (Fig. 6D; F(3, 16) =8.616, p,0.05). These results suggest
that the downregulation of Flk1 following chronic CORT
exposure is mediated through GR. Since we found a significant
reduction in GR following CORT exposure, we examined the
possible interaction between GR and Flk1 in neurons. We found
coprecipitated Flk1 following immunoprecipitation with anti-GR
antibody (Fig. 6E). Next, we examined coprecipitated GR after
immunoprecipitation with anti-Flk1 antibody. We found signifi-
cant coprecipitated GR in cortical neurons following immunopre-
cipitation with anti-Flk1 antibody (Fig. 6F). Chronic CORT
treatment significantly reduced the coprecipitated GR as com-
pared to vehicle treatment (Fig. 6G; t=2.92, df=6, p=0.038).
Reduced Flk1 and GR Protein Levels in Prefrontal Cortex
of Schizophrenia Subjects
Studies were also carried out using postmortem prefrontal
cortex samples from schizophrenia and control subjects. Western
blot analysis showed a significant reduction in Flk1 protein levels
in prefrontal cortex of schizophrenia subjects as compared to
controls (Fig. 7A; t=2.282, df=16, p=0.0365). In addition, we
found a significant reduction in GR protein levels in samples from
schizophrenia subjects (Fig. 7B; t=3.795, df=16, p=0.001).
Collectively, these results extend our findings on Flk1-GR
interaction in cortical neurons following CORT exposure.
CORT Treatment Did Not Change Body Weight and
Water Intake in Mice
There were no differences in relative body weight gain during
the experiment or water intake in mice treated with vehicle or
CORT (data not shown).
Discussion
Our data report the inhibitory effects of long-term continuous
CORT treatment on Flk1 expression in mouse frontal cortex.
Chronic stress and exogenous glucocorticoid exposure are known
to result in neurochemical and behavioral abnormalities in
rodents. Our studies have used 1 mM CORT in the in vitro
studies and the above concentration has been shown to produce
neuroprotective effects when the neurons are exposed to CORT
for shorter time periods such as 5 to 15 min [1]. Although acute
CORT treatment was found to be neuroprotective, the chronic
treatment of CORT has been shown to cause adverse effects in
central nervous system [7]. The dose and duration of CORT used
(5 g/kg) in our in vivo study has previously been shown to cause
anxiety and depression-like behavior in mice [5]. Our studies show
that long-term continuous CORT exposure dramatically reduces
Flk1 protein levels in cortical neurons in vitro, and frontal cortex
and serum in vivo. Although we did not find any neuronal cell
death even at 72 h following CORT exposure, the changes in Flk1
protein levels observed in our study may have a direct impact on
the neuronal cell proliferation. It is well known that Flk1 plays an
important role in neurogenesis [8]. A recent study has reported
inhibition of neurogenesis following 5 mg/kg CORT administra-
tion for 7 weeks [5]. In the present study, we found a decrease in
serum CORT levels in mice treated with CORT for 7 weeks. It is
known that the circulating glucocorticoids exert ‘feedback’ to the
HPA axis to turn off the glucocorticoid secretion and maintain the
right range of glucocorticoids [39]. In addition, exogenous CORT
treatment has been shown to flatten the diurnal CORT rhythm
rather than an absolute increase in circulating CORT levels [40].
In the present study, the blood samples were collected between 3
p.m. and 4 p.m. It has been reported that CORT treatment
inhibits the normal p.m. rise in peripheral CORT levels in
rodents, whereas control animals demonstrate a normal circadian
rhythm of CORT [41].
Figure 4. PI3K signaling is not involved in long-term contin-
uous CORT-induced increases in VEGF protein levels. (A) VEGF
protein levels were determined by western blotting analysis in neuronal
cell lysates treated with LY294002 (LY; 20 mM) for 48 h. CON means
DMSO treatment. Data represent mean6SE (n=6) expressed as fold
change in VEGF protein levels as compared to CON. *P,0.05
(Bonferroni’s test). (B) Pretreatment with LY did not prevent CORT-
induced induction in VEGF protein levels in neurons. Cortical neurons at
DIV 5 were treated with LY (20 mM) for 30 min followed by CORT (1 mM)
exposure for 48 h. VEGF protein levels were determined in cell lysates
by western blot analysis. CON means DMSO treatment. Data represent
mean6SE (n=6) expressed as fold change in VEGF protein levels as
compared to CON. *P,0.05 (Bonferroni’s test).
doi:10.1371/journal.pone.0020198.g004
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cortex, we investigated the effects of CORT on signaling proteins
downstream of Flk-1. The binding of VEGF to its tyrosine kinase
receptors induces dimerization and autophosphorylation of the
tyrosine residues [42]. Two high affinity tyrosine kinase receptors
of VEGF, Flt-1 and KDR/Flk-1, are expressed on the cell
membrane of neurons [10]. Most of the VEGF effects on
neuroplasticity including neurogenesis and cognition are mediated
by interaction with KDR/Flk-1 [11]. As the major downstream
target of KDR/Flk-1, Akt signaling pathway is an important
mediator of neuroplasticity [14]. Following treatment with
CORT, a reduction in phosphoAkt (ser273) levels was found in
cortical neurons. The changes in Akt signaling following CORT
treatment was further confirmed by a significant reduction in
phospho-mTOR levels, one of Akt’s downstream effector
molecules. We also found a significant increase in phospho-PTEN
levels, an upstream regulator of PI3K/Akt signaling. PTEN is one
of the most studied regulators of Akt activity. PTEN regulates the
PI3K/Akt signaling by controlling the levels of phosphatidylino-
sitol-3,4,5-trisphosphate (PIP3). The balance between PI3K and
Figure 5. Chronic CORT-induced Flk1 regulation is mediated through calcium. (A) Calcium chelator BAPTA-AM blocked CORT (CORT)-
induced reduction in Flk1 protein levels. BAPTA-AM (50 mM) was applied 30 min before CORT (1 mM) treatment to cultured neurons at DIV 5. Cell
lysates were collected at 48 h after CORT treatment and Flk1 protein levels were determined by western blot analysis. CON means DMSO treatment.
Data represent mean6SE (n=5) expressed as fold change in Flk1 protein levels as compared to CON. *P,0.01 versus CON; #P,0.01 versus CORT
(Bonferroni’s test). (B) Chronic CORT treatment increases NCS-1 protein levels in neurons. CORT (CORT; 1 mM) was applied to mouse primary cortical
neurons at DIV 5. NCS-1 protein levels were determined by western blotting analysis at 48 h following CORT treatment. CON means DMSO treatment.
Data represent mean6SE (n=5) expressed as fold change in NCS-1 protein levels as compared to CON. *P,0.01 (Bonferroni’s test). (C) Chronic CORT
treatment increases NCS-1 protein levels in mouse frontal cortex. NCS-1 protein levels in frontal cortex of mice treated with CORT (5 mg/kg) or vehicle
control (CON; 0.45% hydroxypropyl-b-cyclodextrin) for 7 weeks were determined by western blot analysis. Data represent mean6SE (n=6) expressed
as fold change in NCS-1 protein levels as compared to CON. b-actin is the loading control.*P,0.05 (Bonferroni’s test).
doi:10.1371/journal.pone.0020198.g005
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downstream activity of Akt. Activation of PTEN has been shown
to result in the inhibition of Akt and other downstream targets
including mTOR. This serine–threonine-kinase member of the
PI3K-family recently gained major interest as therapeutic target
due to its key regulatory role in various cellular functions [43].
Thus, long-term continuous CORT treatment inhibits a complex
pathway comprised of PI3K, Akt and mTOR kinases, which
regulates a number of cellular functions in CNS [44]. Interestingly,
a recent study has shown that the blockade of mTOR signaling
completely blocked ketamine induction of synaptogenesis and
behavioral responses in animal models of depression [45].
Since we found a significant inhibitory effect of CORT on Flk1
signaling in neurons, we next examined the mechanisms of Flk1
regulation under long-term continuous CORT exposure. Our
studies on VEGF protein levels found a significant increase in
VEGF protein levels both in vivo and in vitro following CORT
exposure in frontal cortex. However, we found a significant
reduction in serum VEGF protein levels in mice treated with
CORT for 7 weeks. These data suggest that a feedback
mechanism may operate to increase VEGF production in cortex
in response to inhibition of the VEGF signaling pathway.
However, the possibility of increase in VEGF in cortex as a
response to reduction in peripheral VEGF protein levels following
CORT treatment can not be ruled out. Such an increase in VEGF
in cortex could result in inhibition of Flk1 signaling and reduction
in Flk1 levels in periphery. But, further studies are warranted to
understand the above possible mechanisms. It is important to note
that PI3K signaling also plays an important role on VEGF
regulation [46]. To determine whether the changes observed in
PI3K pathway following CORT exposure is upstream to VEGF
we conducted studies using specific inhibitors of the above
Figure 6. GR downregulation is involved in chronic CORT-induced downregulation of Flk1. (A) GR downregulation following chronic
CORT exposure in neurons. CORT (CORT; 1 mM) was applied to mouse primary cortical neurons at DIV 5. GR protein levels were determined by
western blotting analysis at 48 h following CORT treatment. CON means DMSO treatment. Data represent mean6SE (n=5) expressed as fold change
in GR protein levels as compared to CON. *P,0.05 (t test). (B) Chronic CORT treatment increases GR protein levels in mouse frontal cortex. GR protein
levels in frontal cortex of mice treated with CORT (5 mg/kg) or vehicle control (CON; 0.45% hydroxypropyl-b-cyclodextrin) for 7 weeks were
determined by western blot analysis. Data represent mean6SE (n=5) expressed as fold change in GR protein levels as compared to CON. b-actin is
the loading control.*P,0.05 (t test). (C) RU486 (RU, a GR antagonist) blocked CORT-induced reduction in GR protein levels. RU (1 mM) was applied
30 min before CORT (1 mM) treatment to cultured neurons at DIV5. Cell lysates were collected at 48 h after CORT treatment and GR protein levels
were determined by western blot analysis. CON means DMSO treatment. Data represent mean6SE (n=5) expressed as fold change in GR protein
levels as compared to CON. *P,0.01 versus CON; #P,0.01 versus CORT (Bonferroni’s test). (D) RU486 (RU, a GR antagonist) blocked CORT-induced
reduction in Flk1 protein levels. Data represent mean6SE (n=5) expressed as fold change in Flk1 protein levels as compared to CON. *P,0.01 versus
CON; #P,0.01 versus CORT (Bonferroni’s test). (E) Western blot analysis of Flk1 protein expression after immunoprecipitation with GR antibody in
lysates collected from DIV6 neurons. NoAb: no anti-GR antibody; total: 10% input from total cell lysates. (F) Western blot analysis of GR protein
expression after immunoprecipitation with Flk1 antibody in lysates collected from DIV6 neurons. NoAb: no anti-Flk1 antibody. (G)
Immunoprecipitation of Flk1 in cell lysates from corticosterone (CORT) or vehicle control (CON; DMSO) treated for 48 h. Western blotting was
performed with anti-GR and anti-Flk1 antibodies. Data represent mean6SE (n=4) expressed as fold change in GR protein levels (normalized to Flk1
protein levels) as compared to CON. *P,0.05 versus CON (t test).
doi:10.1371/journal.pone.0020198.g006
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significant effect of PI3K inhibitor on VEGF protein levels in
CORT-treated cells. These results suggest that PI3K signaling
may not be involved in the regulation of VEGF expression under
CORT exposure.
Ca
2+ is an important intracellular messenger in neurons,
regulating a variety of neuronal processes such as neurotransmis-
sion and signal transduction. At the cellular level, glucocorticoid-
induced elevations in [Ca
2+] result in changes in synaptic plasticity
and neuronal excitability [47,48]. NCS-1 is one of the members of
a large family of EF-hand Ca
2+-binding proteins, which may act as
Ca
2+ sensors or Ca
2+ buffers in mediating the actions of Ca
2+ [49].
The increased expression of NCS-1 protein as well as the
inhibition of CORT-induced reduction in Flk1 protein levels by
BAPTA-AM in our study suggests that Ca
2+ may be in involved in
mediating CORT effects on Flk1 expression. However, the caveat
exists that the increased expression of NCS-1 may be in response
to neuronal damages induced by CORT exposure. In accordance
with this, we found little loss of cells in CORT-treated cortical
neurons. This lack of cell death would be the result of the
increased expression level of endogenous NCS-1 in the neurons.
Because evidence indicates that chronic stress leads to upregula-
tion of multiple antiapoptotic molecules as an adaptive response
[50], it is possible that the neuronal insults induced by long-term
continuous CORT exposure upregulates NCS-1 expression and
promotes cellular survival in neurons. Interestingly, an up-
regulation of NCS-1 has also been reported in the cortex of
schizophrenic and bipolar patients, demonstrating the involve-
ment of NCS-1 in neuropsychiatric disorders [51]. Although the
underlying mechanism of changes in NCS-1 expression in
schizophrenia and bipolar disorder is not known, it might be
associated with the altered Ca
2+ signaling reported in these
disorders [52].
A reduction in GR-Flk1 interaction was found in cortical
neurons following CORT exposure. The reduction in GR-Flk1
interaction might be as a result of the downregulation of GR
protein levels by CORT. Chronic glucocorticoid has been shown
to downregulate the interaction of GR with TrkB, another tyrosine
kinase receptor in neurons [53]. The reduction in Flk1 protein
levels following CORT was inhibited by GR antagonist, RU486.
Flk1 might be part of a protein complex with GR, and the
reduction in GR following CORT exposure might result in the
dissociation of Flk1 from GR and Flk1 signaling is thus inhibited.
Similar mechanisms have been suggested for GR-TrkB interaction
in neurons [53] and GR-TCR interaction in T-cells [54].
Together, our data suggest the possible role of GR in mediating
CORT effects on Flk1.
We found a significant reduction in Flk1 and GR protein levels
in prefrontal cortex samples from schizophrenia subjects. Al-
though the schizophrenia and control subjects in our sample set
are not well matched in their demographic variables we did not
find any significant difference between controls and schizophrenia
subjects in any of the confounding variables, such age at death,
PMI, brain weight, refrigeration interval, gender and duration of
illness. In addition, no significant correlation was found between
the protein levels of either GR or Flk1 levels and the above
confounding variables (data not shown). However, we can not rule
out the possible influence of pH on the above protein levels [55].
Unfortunately, the sample cohort used in the present study lack
the information on pH.
In conclusion, this study demonstrates altered Flk1 expression in
the frontal cortex in response to long-term continuous CORT
treatment (Fig. 8). This could have relevance in understanding
neurobiological effects of glucocorticoids and of chronic stress.
Materials and Methods
Animals
All in vivo experiments were conducted in adult male CD1 mice
(Charles River Laboratories, Wilmington, MA, USA). All CORT-
treated mice were 7–8 weeks old and weighed 25–30 g at the
beginning of the treatment. Mice were maintained on a 12-h light–
dark cycle with the lights on at 0700 hours, and were housed four
per cage. Food and water were provided ad libitum. All in vitro
experiments were done in cerebral cortical neuronal cultures from
embryonic day 16 mouse fetuses. Animal use procedures were
performed after being reviewed and approved by Medical College
of Georgia, Committee on Animal Use for Research and Veterans
Affairs Medical Center Subcommittee on Animal Use. Procedures
were consistent with the Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC) guidelines
as per Public Health Service Policy on Humane Care and Use of
Laboratory Animals.
Figure 7. Reduced Flk1 and GR protein levels in prefrontal
cortex of schizophrenia subjects. (A) Reduced Flk1 protein levels in
prefrontal cortex samples from schizophrenia subjects. Flk1 protein
levels in the prefrontal cortex of schizophrenia (SZ; n=10) and control
(CON; n=8) subjects were determined by western blot analysis. Data
represent mean6SE expressed as fold change in Flk1 protein levels as
compared to CON. *P,0.05 versus CON (t test). (B) Reduced GR protein
levels in prefrontal cortex samples from schizophrenia subjects (SZ;
n=10) as compared to control subjects (CON; n=8). Data represent
mean6SE expressed as fold change in GR protein levels as compared to
CON. *P,0.05 versus CON (t test).
doi:10.1371/journal.pone.0020198.g007
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At the end of 7 week-treatment, mice were killed by
decapitation, and the frontal cortex from experimental and
control mice were separately dissected. The dissection level for
the frontal cortex, 2.34 mm anterior to bregma, was chosen
according to the mouse brain stereotaxic coordinates [26]. The
tissue samples were homogenized in radioimmune precipitation
assay (RIPA) buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl,
0.1% sodium dodecyl sulfate (SDS), 1% Nonidet P-40, and 1%
sodium deoxycholate) for western blotting. RIPA buffer enables
efficient cell lysis and protein solubilization while avoiding protein
degradation and interference with immunoreactivity. This buffer
was supplemented with a protease inhibitor cocktail (Sigma)
containing 104 mM 4-(2-Aminoethyl) benzenesulfonyl fluoride
hydrochloride (AEBSF), 0.08 mM aprotinin, 2 mM leupeptin,
4 mM bestatin, 1.5 mM pepstatin A and 1.4 mM E-64. After
15 min incubation on ice, the extracts were clarified by
centrifugation at 15,000 g for 15 min at 4uC and stored at
270uC. Protein concentration was determined by the bicincho-
ninic acid method (BCA Protein Assay Kit, Sigma).
Cerebral Cortical Neuronal Cultures
Mouse cortical neurons were cultured as described previously
[26]. Briefly, cerebral cortices from CD-1 murine embryos (E16)
were aseptically dissected and plated at 3.5610
5 cells per well on
polyethyleneimine-coated 6-well plates. Neurons were cultured in
Neurobasal medium supplemented with B27, 2 mM L-glutamine,
and antibiotics (Invitrogen). On the third day in vitro (DIV3), media
was replaced with Neurobasal supplemented with B27 minus
antioxidants, glutamine, and antibiotics. Purified neuronal cultures
were routinely .97% neurons, as assessed by MAP-2 immuno-
staining. Neurons were used for treatments between DIV 5 and 7.
Following treatments in culture, cells were washed in Phosphate
Buffered Saline (PBS) and collected in ice-cold RIPA buffer.
Protein concentration was determined by the BCA method.
Drug Treatment
In vivo studies. CORT (4-pregnen-11b-diol-3 20-dione 21-
hemisuccinate; Sigma, St Louis, MO, USA) was dissolved in
vehicle (0.45% hydroxypropyl-b-cyclodextrin, Sigma, St Louis,
MO, USA). CORT (35 mg/mL, equivalent to 5 mg/kg/day) was
delivered ad libitum in the drinking water. The dose and duration of
CORT treatment in mice were selected based on an earlier study
[5] where the above dose and duration of treatment with CORT
induced anxiety and depression-like behaviors in mice. Control
mice received 0.45% hydroxypropyl-b-cyclodextrin as vehicle.
In vitro studies. Primary cortical neurons were treated with
CORT (1 mM) or vehicle (DMSO). CORT concentration for in
vitro study was selected based on an earlier study [1] where acute
exposure with above dose was found neuroprotective in primary
cortical neurons. The treatment was carried out with a single
application of CORT or vehicle in 48 h treatment group whereas
the solutions were replenished after 48 h in the 72 h treatment
groups. Neuronal cell viability was assessed at 48, 72 and 96 h
following CORT exposure and Flk1 expression was examined at
12, 24, 48 and 72 h after CORT treatment. The analyses of other
proteins were carried out at 48 and/or 72 h following CORT
exposure.
Determination of neuronal cell viability in culture
Neuronal cell viability in culture was assessed using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) re-
duction assay [27]. Briefly, following treatments, 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide [5 mg/mL
in phenol-red free Roswell Park Memorial Institute medium
(RPMI)-1640] was added to each well for 4 h at 37uC. Following
incubation, formazan salts were dissolved in acidic isopropanol
and absorbance was measured using a VERSAmax microplate
reader (Molecular Devices, Sunnyvale, CA, USA) at 540 nm using
a reference wavelength of 690 nm. All readings were compared
with the control treatment group.
Western blot analysis
Equal amounts of protein were resolved in SDS–polyacrylamide
gels and transferred electrophoretically onto a nitrocellulose
membrane. The membrane was blocked for 1 h in PBS solution
with the detergent Tween 20 (PBST; 3.2 mM Na2HPO4,
0.5 mM KH2PO4, 1.3 mM KCl, 135 mM NaCl, 0.05% Tween
20, pH 7.4.) and 5% non-fat milk or 5% BSA. The membranes
were incubated overnight with the indicated primary antibodies.
The primary antibodies used were anti-phospho- Akt, anti-Akt,
anti-Flk-1, anti-phospho-mTOR, anti-mTOR, anti-phospho-
PTEN, anti-PTEN (all antibodies were from Cell signaling,
Beverly, MA, USA), anti-GR, anti-NCS-1 (both were from Santa
Cruz Biotech, CA, USA) and anti-b-actin (Sigma, St Louis, MO,
USA). The membranes were washed again with PBST then
incubated with secondary antibody for 1 h. Proteins were
visualized by enhanced chemiluminescence. The films were
subsequently scanned, and band intensity was quantified by
densitometry software (Image J, NIH). The western blot data for
Flk1, GR and NCS-1 were corrected for corresponding b-actin
values. The data for phosphorylated forms of proteins were
corrected for corresponding total protein values. For VEGF, tissue
Figure 8. Proposed model showing the effects of corticoste-
rone on VEGF/Flk1 signaling pathway in mouse frontal cortex.
The signaling events induced by corticosterone (CORT) are mediated
through the Glucocorticoid receptor (GR). The reduction in Flk1 levels
following long-term continuous CORT exposure results in the activation
of PTEN, but inhibition of Akt and mTOR phosphorylation. The effects of
CORT on Flk1 are mediated through calcium (Ca
2+). CORT exposure
results in increased levels of VEGF in cortex. The role of VEGF in Flk1
regulation (or vice versa) under CORT exposure remains unknown. Solid
arrows represent activation, whereas dashed arrows represent inhibi-
tion of the pathways.
doi:10.1371/journal.pone.0020198.g008
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described previously [28]. In brief, the beads were pelleted at
5000 g for 1 min, washed in 400 mM NaCl and 20 mM Tris, and
loaded onto a 4 to 20% gradient Tris glycine precast gel (Bio-Rad
Laboratories). After blocking, the membrane was incubated with
VEGF primary antibody (Calbiochem, Gibbstown, NJ, USA). The
band was visualized and quantified as described above.
Serum VEGF assay
Quantification of serum VEGF was performed with a DuoSet
enzyme-linked immunosorbent assay (ELISA) (R&D Systems,
Minneapolis, IN, USA) according to the manufacturer’s specifi-
cations.
Serum CORT assay
At the end of 7-week treatment, mice were killed by
decapitation (1500–1600 h). Trunk blood was harvested and
serum collected for CORT analyses. Serum was assayed for
CORT using a quantitative competitive enzyme immunoassay kit
(Cat # KA0468 V.04) from Abnova, Taipei according to
manufacturer’s instructions. Intra-assay and inter-assay measures
of variability were 4.8% and 7.3% respectively. Serum concen-
trations were determined from a software generated standard
curve and reported in ng/mL.
Serum Flk1 assay
Serum samples were collected as described above and soluble
Flk1 protein levels were determined with a quantitative sandwich
enzyme immunoassay kit (#MVR200B; R&D Systems) according
to the manufacturer’s specifications.
Human prefrontal cortex samples
The prefrontal cortex samples from schizophrenia and control
subjects were obtained from the Human Brain and Spinal Fluid
Resource Center (Los Angeles, California, USA). A description on
the demographic details is given in Table 1. No significant
difference was found between controls and schizophrenia subjects
in any of the confounding variables, such age at death, PMI, brain
weight, refrigeration interval, gender and duration of illness. The
samples were shipped frozen and stored at 2 80uC until analysis.
Grey matter was removed from a 1.5–2.0 cm thick coronal slab of
the frontal cortex anterior to the corpus callosum and the
prefrontal cortex was dissected [29]. Prefrontal cortex tissue was
homogenized in a homogenizing buffer containing 20 mM Tris–
HCl (pH 7.4), 2 mM EGTA, 5 mM EDTA, 1.5 mM pepstatin,
2 mM leupeptin, 0.5 mM phenylmethylsulfonyl fluoride, 0.2 U/
mL aprotinin, and 2 mM dithiothreitol, using a Polytron
homogenizer. The homogenate was centrifuged at 15,000 rpm
for 15 min at 4uC. Protein concentration in the supernatant was
determined with BCA Reagent. Flk1 and GR protein levels were
determined by western blot analysis as described above using b-
actin as a loading control [30].
Statistical Analysis
Data are expressed as mean6SE. Two-way ANOVA followed
by post hoc one-way ANOVA with Bonferroni’s multiple
comparison test was used in analyzing data from time dependent
studies. Comparisons between multiple groups were done by one-
way ANOVA. Individual comparisons between two groups were
performed with Student’s t test. Probability (P) values of less than
5% were considered significant.
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